Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Overview

The rationale for this retrospective study is to evaluate the efficacy and safety of abatacept and rituximab treatment of ILLD in a cohort of pediatric patients with different forms of PID, who received one of the two therapy regimens predominantly based on the lesions histopathology.

Full Title of Study: “Retrospective Chart Review of Children With Primary Immunodeficiencies (PID) Who Received Targeted Therapy of Interstitial Lymphocytic Lung Disease (ILLD) With Abatacept or Rituximab.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: September 2021

Detailed Description

Primary immunodeficiencies (PID) represent a heterogeneous group of more than 400 inherited conditions with associated immune dysfunctions. Though severe recurrent/chronic infections are the main cause of mortality and morbidity in PID, immune dysregulation manifesting with oncological and autoimmune or autoinflammatory conditions involving various organs and systems have been the focus of research in the recent years. The interstitial lymphocytic lung disease (ILLD) is one of the recently characterized non-malignant PID complications. Immune dysregulation in ILLD causes reactive bronchi-associated lymphoid tissue (BALT) hyperplasia that manifests in several pathomorphological forms: follicular bronchiolitis (FB), nodular lymphoid hyperplasia (NLH), and lymphocytic interstitial pneumonia (LIP). Treatment of ILLD patients with various immunosuppressive drugs leads to inconsistent results ranging from partialtransient effect to no effect at all and has been often associated with adverse effects and an increase in infections' rate. Therefore there is a need for targeted therapy of ILLD. In small cohorts of adult PID patients rituximab in combination with azathioprine proved to be effective. Yet, the reports are scarce and there is currently no consensus on ILLD treatment, especially in children. The study will collect and analyze information on the effectiveness and safety of ILLD monotherapy with rituximab or abatacept, chosen predominantly based on the pathomorphological characteristics of lymphoid infiltration, as well as genetic defects, in a cohort of pediatric patients with PID.

Interventions

  • Drug: Rituximab
    • 375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
  • Drug: Abatacept
    • 10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.

Arms, Groups and Cohorts

  • group 1(rituximab)
  • group 2 (abatacept)

Clinical Trial Outcome Measures

Primary Measures

  • Dynamics of severity clinical and radiological symptoms
    • Time Frame: before the time the first dose of study treatment was administered
    • Dynamics of severity clinical and radiological symptoms of ILLD using scale score.
  • Dynamics of severity clinical and radiological symptoms
    • Time Frame: 3 months of treatment
    • Dynamics of severity clinical and radiological symptoms of ILLD using scale score.
  • Dynamics of severity clinical and radiological symptoms
    • Time Frame: 6 months of treatment
    • Dynamics of severity clinical and radiological symptoms of ILLD using scale score.
  • Dynamics of severity clinical and radiological symptoms
    • Time Frame: 1 year of treatment
    • Dynamics of severity clinical and radiological symptoms of ILLD using scale score.

Secondary Measures

  • Frequency of adverse events
    • Time Frame: from the time the first dose of study treatment was administered until 12 mo of treatment
  • quality of life of patients
    • Time Frame: before the time the first dose of study treatment was administered until 12 mo of treatment
    • The quality of life of patients before and after therapy

Participating in This Clinical Trial

Inclusion Criteria

1. Histological and/or radiological diagnosis of ILLD. 2. Treatment with rituximab or abatacept for at least 12 months. 3. No signs of ongoing infectious pulmonary process at the start of the treatment. 4. Regular IG substitution with trough IgG levels > 5g/l. Exclusion criteria are nonadherence to therapy.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Anna Shcherbina, MD, PhD, +7(495)2876570, shcher26@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.